Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Peripheral Intervention Drug-Eluting Devices Market by Procedure (Plain Old Balloon Angioplasty, Percutaneous Transluminal Angioplasty) and by Type (Drug Eluting Balloons, Drug Eluting Stents): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03885

Pages: NA

Charts: NA

Tables: NA

Drug eluting devices are devices that are coated with anti-proliferated agent. These devices exert antirestenotic efficacy on the vessel wall to remove the blockade within the blood vessels caused by deposition of plaque.

Factors such as rise in geriatric population, high incidence of peripheral artery disease (PAD), advancement of technology in peripheral intervention devices, increased demand for minimal invasive procedures, and demand for drug coated devices to show antirestenotic effect drive the market growth. However, availability of conventional treatments and product recalls restrain the market growth. Moreover, introduction of bioresorbable stents and development of healthcare infrastructure regarding peripheral diseases in untapped market provide opportunities for the market growth.

The peripheral intervention drug-eluting devices market is segmented on the basis of procedure, type, and region. On the basis of procedure, it is divided into plain old balloon angioplasty (POBA) and percutaneous transluminal angioplasty (PTA). On the basis on type, it is classified into drug-eluting balloons and drug-eluting stents. By geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players in the market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cardinal Health, B. Braun Melsungen AG, Biosensors International Group Ltd., C.R. Bard, Inc., St. Jude Medical, Inc., The Lubrizol Corporation, and Terumo Corporation.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by product helps in understanding the various procedures used for treatment of peripheral intervention.
  • Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the global market.

 Key Market Segments

  • By Procedure
    • Plain Old Balloon Angioplasty
    • Percutaneous Transluminal Angioplasty
  • By Type
    • Drug Eluting Balloons
    • Drug Eluting Stents
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Terumo Corporation
  • Cardinal Health
  • St. Jude Medical, Inc.
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Medtronic plc
  • C.R. Bard, Inc.
  • Boston Scientific Corporation
  • Biosensors International Group Ltd.
  • The Lubrizol Corporation

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET, BY PROCEDURE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Procedure

    • 4.2. Plain Old Balloon Angioplasty

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Percutaneous Transluminal Angioplasty

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET, BY TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Type

    • 5.2. Drug Eluting Balloons

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Drug Eluting Stents

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Procedure

      • 6.2.3. Market Size and Forecast, By Type

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Peripheral Intervention Drug-eluting Devices Market

        • 6.2.5.1. Market Size and Forecast, By Procedure
        • 6.2.5.2. Market Size and Forecast, By Type

      • 6.2.6. Canada Peripheral Intervention Drug-eluting Devices Market

        • 6.2.6.1. Market Size and Forecast, By Procedure
        • 6.2.6.2. Market Size and Forecast, By Type

      • 6.2.7. Mexico Peripheral Intervention Drug-eluting Devices Market

        • 6.2.7.1. Market Size and Forecast, By Procedure
        • 6.2.7.2. Market Size and Forecast, By Type

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Procedure

      • 6.3.3. Market Size and Forecast, By Type

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Peripheral Intervention Drug-eluting Devices Market

        • 6.3.5.1. Market Size and Forecast, By Procedure
        • 6.3.5.2. Market Size and Forecast, By Type

      • 6.3.6. Germany Peripheral Intervention Drug-eluting Devices Market

        • 6.3.6.1. Market Size and Forecast, By Procedure
        • 6.3.6.2. Market Size and Forecast, By Type

      • 6.3.7. Italy Peripheral Intervention Drug-eluting Devices Market

        • 6.3.7.1. Market Size and Forecast, By Procedure
        • 6.3.7.2. Market Size and Forecast, By Type

      • 6.3.8. Spain Peripheral Intervention Drug-eluting Devices Market

        • 6.3.8.1. Market Size and Forecast, By Procedure
        • 6.3.8.2. Market Size and Forecast, By Type

      • 6.3.9. UK Peripheral Intervention Drug-eluting Devices Market

        • 6.3.9.1. Market Size and Forecast, By Procedure
        • 6.3.9.2. Market Size and Forecast, By Type

      • 6.3.10. Russia Peripheral Intervention Drug-eluting Devices Market

        • 6.3.10.1. Market Size and Forecast, By Procedure
        • 6.3.10.2. Market Size and Forecast, By Type

      • 6.3.11. Rest Of Europe Peripheral Intervention Drug-eluting Devices Market

        • 6.3.11.1. Market Size and Forecast, By Procedure
        • 6.3.11.2. Market Size and Forecast, By Type

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Procedure

      • 6.4.3. Market Size and Forecast, By Type

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Peripheral Intervention Drug-eluting Devices Market

        • 6.4.5.1. Market Size and Forecast, By Procedure
        • 6.4.5.2. Market Size and Forecast, By Type

      • 6.4.6. Japan Peripheral Intervention Drug-eluting Devices Market

        • 6.4.6.1. Market Size and Forecast, By Procedure
        • 6.4.6.2. Market Size and Forecast, By Type

      • 6.4.7. India Peripheral Intervention Drug-eluting Devices Market

        • 6.4.7.1. Market Size and Forecast, By Procedure
        • 6.4.7.2. Market Size and Forecast, By Type

      • 6.4.8. South Korea Peripheral Intervention Drug-eluting Devices Market

        • 6.4.8.1. Market Size and Forecast, By Procedure
        • 6.4.8.2. Market Size and Forecast, By Type

      • 6.4.9. Australia Peripheral Intervention Drug-eluting Devices Market

        • 6.4.9.1. Market Size and Forecast, By Procedure
        • 6.4.9.2. Market Size and Forecast, By Type

      • 6.4.10. Thailand Peripheral Intervention Drug-eluting Devices Market

        • 6.4.10.1. Market Size and Forecast, By Procedure
        • 6.4.10.2. Market Size and Forecast, By Type

      • 6.4.11. Malaysia Peripheral Intervention Drug-eluting Devices Market

        • 6.4.11.1. Market Size and Forecast, By Procedure
        • 6.4.11.2. Market Size and Forecast, By Type

      • 6.4.12. Indonesia Peripheral Intervention Drug-eluting Devices Market

        • 6.4.12.1. Market Size and Forecast, By Procedure
        • 6.4.12.2. Market Size and Forecast, By Type

      • 6.4.13. Rest of Asia Pacific Peripheral Intervention Drug-eluting Devices Market

        • 6.4.13.1. Market Size and Forecast, By Procedure
        • 6.4.13.2. Market Size and Forecast, By Type

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Procedure

      • 6.5.3. Market Size and Forecast, By Type

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Peripheral Intervention Drug-eluting Devices Market

        • 6.5.5.1. Market Size and Forecast, By Procedure
        • 6.5.5.2. Market Size and Forecast, By Type

      • 6.5.6. South Africa Peripheral Intervention Drug-eluting Devices Market

        • 6.5.6.1. Market Size and Forecast, By Procedure
        • 6.5.6.2. Market Size and Forecast, By Type

      • 6.5.7. Saudi Arabia Peripheral Intervention Drug-eluting Devices Market

        • 6.5.7.1. Market Size and Forecast, By Procedure
        • 6.5.7.2. Market Size and Forecast, By Type

      • 6.5.8. UAE Peripheral Intervention Drug-eluting Devices Market

        • 6.5.8.1. Market Size and Forecast, By Procedure
        • 6.5.8.2. Market Size and Forecast, By Type

      • 6.5.9. Argentina Peripheral Intervention Drug-eluting Devices Market

        • 6.5.9.1. Market Size and Forecast, By Procedure
        • 6.5.9.2. Market Size and Forecast, By Type

      • 6.5.10. Rest of LAMEA Peripheral Intervention Drug-eluting Devices Market

        • 6.5.10.1. Market Size and Forecast, By Procedure
        • 6.5.10.2. Market Size and Forecast, By Type

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Medtronic Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Boston Scientific Corporation

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Abbott Laboratories

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Cardinal Health

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. B. Braun Melsungen AG

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Biosensors International Group Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. C.R. Bard, Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. St. Jude Medical, Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. The Lubrizol Corporation

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Terumo Corporation

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR PLAIN OLD BALLOON ANGIOPLASTY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR DRUG ELUTING BALLOONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR DRUG ELUTING STENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. NORTH AMERICA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 11. U.S. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 12. U.S. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 13. CANADA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 14. CANADA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 15. MEXICO PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. EUROPE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. FRANCE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 22. GERMANY PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. ITALY PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 25. ITALY PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. SPAIN PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. UK PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 29. UK PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. RUSSIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. REST OF EUROPE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. ASIA-PACIFIC PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. CHINA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 38. CHINA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 39. JAPAN PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. INDIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 42. INDIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SOUTH KOREA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. AUSTRALIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. THAILAND PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. MALAYSIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. INDONESIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. LAMEA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. BRAZIL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 60. SOUTH AFRICA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. SAUDI ARABIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. UAE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 65. UAE PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. ARGENTINA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. REST OF LAMEA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 71. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 72. MEDTRONIC PLC: OPERATING SEGMENTS
  • TABLE 73. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 74. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 76. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 77. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 78. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 79. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 81. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 82. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 83. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 84. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 86. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 87. CARDINAL HEALTH: OPERATING SEGMENTS
  • TABLE 88. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 89. CARDINAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. B. BRAUN MELSUNGEN AG: KEY EXECUTIVES
  • TABLE 91. B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • TABLE 92. B. BRAUN MELSUNGEN AG: OPERATING SEGMENTS
  • TABLE 93. B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
  • TABLE 94. B. BRAUN MELSUNGEN AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. BIOSENSORS INTERNATIONAL GROUP LTD.: KEY EXECUTIVES
  • TABLE 96. BIOSENSORS INTERNATIONAL GROUP LTD.: COMPANY SNAPSHOT
  • TABLE 97. BIOSENSORS INTERNATIONAL GROUP LTD.: OPERATING SEGMENTS
  • TABLE 98. BIOSENSORS INTERNATIONAL GROUP LTD.: PRODUCT PORTFOLIO
  • TABLE 99. BIOSENSORS INTERNATIONAL GROUP LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. C.R. BARD, INC.: KEY EXECUTIVES
  • TABLE 101. C.R. BARD, INC.: COMPANY SNAPSHOT
  • TABLE 102. C.R. BARD, INC.: OPERATING SEGMENTS
  • TABLE 103. C.R. BARD, INC.: PRODUCT PORTFOLIO
  • TABLE 104. C.R. BARD, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. ST. JUDE MEDICAL, INC.: KEY EXECUTIVES
  • TABLE 106. ST. JUDE MEDICAL, INC.: COMPANY SNAPSHOT
  • TABLE 107. ST. JUDE MEDICAL, INC.: OPERATING SEGMENTS
  • TABLE 108. ST. JUDE MEDICAL, INC.: PRODUCT PORTFOLIO
  • TABLE 109. ST. JUDE MEDICAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. THE LUBRIZOL CORPORATION: KEY EXECUTIVES
  • TABLE 111. THE LUBRIZOL CORPORATION: COMPANY SNAPSHOT
  • TABLE 112. THE LUBRIZOL CORPORATION: OPERATING SEGMENTS
  • TABLE 113. THE LUBRIZOL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 114. THE LUBRIZOL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. TERUMO CORPORATION: KEY EXECUTIVES
  • TABLE 116. TERUMO CORPORATION: COMPANY SNAPSHOT
  • TABLE 117. TERUMO CORPORATION: OPERATING SEGMENTS
  • TABLE 118. TERUMO CORPORATION: PRODUCT PORTFOLIO
  • TABLE 119. TERUMO CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET
  • FIGURE 3. SEGMENTATION PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET
  • FIGURE 11. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET SEGMENTATION, BY BY PROCEDURE
  • FIGURE 12. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR PLAIN OLD BALLOON ANGIOPLASTY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 15. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR DRUG ELUTING BALLOONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET FOR DRUG ELUTING STENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: PERIPHERAL INTERVENTION DRUG-ELUTING DEVICES MARKET
  • FIGURE 23. TOP PLAYER POSITIONING, 2024
  • FIGURE 24. MEDTRONIC PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 25. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 26. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 27. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. CARDINAL HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. CARDINAL HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. CARDINAL HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. B. BRAUN MELSUNGEN AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. B. BRAUN MELSUNGEN AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. B. BRAUN MELSUNGEN AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. BIOSENSORS INTERNATIONAL GROUP LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. BIOSENSORS INTERNATIONAL GROUP LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. BIOSENSORS INTERNATIONAL GROUP LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. C.R. BARD, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. C.R. BARD, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. C.R. BARD, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. ST. JUDE MEDICAL, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. ST. JUDE MEDICAL, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. ST. JUDE MEDICAL, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. THE LUBRIZOL CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. THE LUBRIZOL CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. THE LUBRIZOL CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. TERUMO CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. TERUMO CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. TERUMO CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Peripheral Intervention Drug-Eluting Devices Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved